BioFocus and Amgen Form Ion Channel Drug Discovery Collaboration.Business Editors/Health/Medical Writers BIOWIRE2K SITTINGBOURNE, England--(BUSINESS WIRE)--Jan. 13, 2003 BioFocus plc (BioFocus), the collaborative drug discovery company, announced today that it has entered into a drug discovery programme with Amgen Inc.(Nasdaq: AMGN) based on exploiting a class of biological targets known as ion channels ion channel n. See channel. . The modulation modulation, in communications modulation, in communications, process in which some characteristic of a wave (the carrier wave) is made to vary in accordance with an information-bearing signal wave (the modulating wave); demodulation is the process by which of ion channels is potentially important in the treatment of a wide range of diseases including cardiovascular and neurological disorders This is a list of major and frequently observed neurological disorders (e.g. Alzheimer's disease), symptoms (e.g.back pain), signs (e.g. aphasia) and syndromes (e.g. Aicardi syndrome). . Under the terms of the agreement, BioFocus will provide Amgen with drug discovery expertise for multiple ion channel targets, including assay development, high throughput screening, chemistry and molecular informatics Same as information technology and information systems. The term is more widely used in Europe. . In return, BioFocus will receive compensation in the form of research fees and milestone payments upon the achievement of certain clinical and commercial events. Specific financial details, ion channel targets, disease areas and commercialisation targets were not disclosed. Dr. David Stone
About BioFocus BioFocus is a pioneering collaborative drug discovery company that applies its comprehensive range of medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. expertise and biological screening capabilities to accelerate its partners' discovery programs. It is a growing and profitable company quoted on the Alternative Investment Market (AIM) of the London Stock Exchange London Stock Exchange London marketplace for securities. It was formed in 1773 by a group of stockbrokers who had been doing business informally in local coffeehouses. and has approximately 190 staff located at three UK science centers near Cambridge and Sittingbourne. BioFocus works with a wide range of global biopharmaceutical companies including Axxima, Biovitrum, GlaxoSmithKline, Millennium, Daiichi, Pfizer, Roche and Teijin. For more details please visit www.biofocus.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion